---
truth_dimension: planned
authority_level: authoritative
mutation_path: roadmap_update
---

# Phase 165 - Code-Production Alignment Checkpoint

Phase 165 reconciles the Phase 161-164 controlled-internal-trial preparation block and confirms the next code-production block.

## Alignment note

Phases 161-164 are present in the active changelog and align as controlled internal trial preparation: controlled internal trial package, trial operator runbook and failure drill UI, trial session evidence capture, and trial replay and restore verification.

## Phase 161-164 implementation reconciliation

| Phase | Evidence reconciled | Phase 165 finding |
| --- | --- | --- |
| 161 | Controlled internal trial package with explicit write/read and read-back validation. | Present as local package evidence; controlled internal trial package is not trial approval. |
| 162 | Trial operator runbook, failure drill UI, stop-condition drill, and escalation guidance. | Present as guidance only; failure drill is guidance only, stop-condition drill is not automated enforcement, and escalation guidance does not activate authority. |
| 163 | Trial session evidence capture with package/runbook linkage and workflow snapshots. | Present as local trial evidence; trial session evidence is not readiness evidence, not release evidence, and not deployment evidence. |
| 164 | Trial replay and restore verification with package/evidence linkage, replay/status comparison, restore/history comparison, mismatch drilldown, and verification panel. | Present as deterministic verification; trial replay/restore verification is not replay repair or recovery promotion. |

## Current controlled-trial preparation status

The current controlled-trial preparation path is aligned:

controlled internal trial package → operator runbook / failure drill → trial session evidence capture → package/evidence read-back validation → replay/status comparison → restore/history comparison → mismatch drilldown → verification panel.

## Controlled internal trial execution blockers

| Blocker area | Phase 165 finding | Next mapped phase |
| --- | --- | --- |
| Execution harness | Missing bounded trial execution harness or deterministic local trial runner. | Phase 166 |
| Trial observability | Missing local observability/error reporting for blocked states, restore issues, replay status, package validation, evidence validation, and verification mismatches. | Phase 167 |
| Evidence review | Missing operator-facing review surface for trial run evidence, notes, failure categories, verification results, stop-condition outcomes, and unresolved blockers. | Phase 168 |
| Evidence-driven fixes | Confirmed trial defects have not yet been remediated through a local beta hardening pass. | Phase 169 |
| Next alignment gate | Release Candidate preparation cannot be considered until after implementation evidence from Phases 166-169 is reconciled. | Phase 170 |

## Authority boundary preservation

| Boundary | Preserved Phase 165 statement |
| --- | --- |
| Trial package | Controlled internal trial package is not trial approval. |
| Runbook | Trial operator runbook is guidance only. |
| Failure drill | Failure drill is guidance only. |
| Stop-condition drill | Stop-condition drill is not automated enforcement. |
| Escalation | Escalation guidance does not activate authority. |
| Evidence | Trial session evidence is not readiness evidence, not release evidence, and not deployment evidence. |
| Replay/restore | Trial replay/restore verification is not replay repair or recovery promotion. |
| Verification | Verification passing is not approval. |
| Blockers | Absence of blockers is not approval. |
| Phase 166 | Controlled trial execution harness, if implemented, is not public/general use, not production use, not release readiness, and not Production Candidate status. |
| Operator decisions | Operator decisions remain local workflow decisions, not release/deployment/public-use approvals. |

## Trial-execution-not-approval statement

Phase 165 permits planning Phase 166 as a bounded local implementation phase only. It does not approve controlled human use, public/general use, production use, production readiness, release readiness, Release Candidate status, Production Candidate status, deployment, publishing, signing, installer/update channels, provider trust, action execution, replay repair, or recovery promotion.

## Phase 166 gate decision

`proceed_with_caveats_to_controlled_internal_trial_execution_harness`

Phase 166 may proceed as the next code-production phase only under explicit local harness constraints.

## Confirmed Phase 166-170 code-production block

| Phase | Title | Required output | Boundary |
| --- | --- | --- | --- |
| 166 | Controlled Internal Trial Execution Harness | Executable trial-run harness behavior or deterministic local trial runner. | No public release, production approval, or trial authority outside explicit local harness constraints. |
| 167 | Trial Observability and Error Reporting | Local trial observability/error reporting surfaces. | No production monitoring claim, background telemetry, or network telemetry. |
| 168 | Trial Evidence Review Surface | UI/evidence review for trial evidence, operator notes, failure categories, verification results, stop-condition outcomes, and unresolved blockers. | Evidence review only; no readiness approval. |
| 169 | Local Beta Hardening Pass | Concrete local-beta hardening code for confirmed trial defects. | No production, release, or public-use approval. |
| 170 | Production-Path Alignment Checkpoint | Alignment-only decision on Release Candidate preparation versus more hardening. | No Release Candidate status, Production Candidate status, readiness, deployment, or public/general use approval. |

Every non-0/5 phase must produce visible UI capability, executable Rust capability, trial execution harness behavior, trial evidence artifact, local observability/error-reporting capability, restore/replay/export verification capability, end-to-end operator workflow improvement, or concrete local-beta hardening code. Safety checks remain embedded in implementation phases and must not become the only product of a non-0/5 phase unless they directly validate a newly introduced executable capability.
